如需更加详细的说明书文档，请联系右侧在线客服索取

使用目的：

本试剂盒用于测定血清、血浆及相关液体样本中的指标含量。

实验原理

本试剂盒应用双抗体夹心法测定标本中指标水平。用纯化的抗体包被微孔板，制成固相抗体，与HRP标记的抗体结合，形成抗体-抗原-酶标抗体复合物，经过彻底洗涤后加底物TMB显色。TMB在HRP酶的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的指标呈正相关。用酶标仪在450nm波长下测定吸光度（OD值），通过标准曲线计算浓度。

试剂盒组成

1	30倍浓缩洗涤液	20ml×1瓶	7	终止液	6ml×1瓶
2	酶标试剂	6ml×1瓶	8	标准品	0.5ml×1瓶
3	酶标包被板	12孔×8条	9	标准品稀释液	1.5ml×1瓶
4	样品稀释液	6ml×1瓶	10	说明书	1份
5	显色剂A液	6ml×1瓶	11	封板膜	2张
6	显色剂B液	6ml×1/瓶	12	密封袋	1个

操作步骤

1. 标准品的稀释：本试剂盒提供原倍标准品一支，用户可在小试管中进行稀释。

2. 加样：分别设空白孔（空白对照孔不加样品及酶标试剂，其余各步操作相同）、标准孔、待测样品孔。在酶标包被板上标准品准确加样50μl，待测样品孔中先加样品稀释液40μl，然后再加待测样品10μl（样品最终稀释度为5倍）。加样将样品加于酶标板孔底部，尽量不触及孔壁，轻轻晃动混匀。

3. 温育：用封板膜封板后置37℃温育30分钟。   

4. 配液：将30倍浓缩洗涤液用蒸馏水30倍稀释后备用

5. 洗涤：小心揭掉封板膜，弃去液体，甩干，每孔加满洗涤液，静置30秒后弃去，如此重复5次，拍干。

6. 加酶：每孔加入酶标试剂50μl，空白孔除外。

7. 温育：操作同3。

8. 洗涤：操作同5。

9. 显色：每孔先加入显色剂A50μl，再加入显色剂B50μl，轻轻震荡混匀，37℃避光显色10分钟.

10. 终止：每孔加终止液50μl，终止反应（此时蓝色立转黄色）。

11. 测定：以空白孔调零，450nm波长依序测量各孔的吸光度（OD值）。 测定应在加终止液后15分钟以内进行。

文献参考：文章标题：Edaravone Dexborneol mitigates pathology in animal and cell culture models of Alzheimer’s disease by inhibiting neuroinflammation and neuronal necroptosis

作者列表：Xu Chong, Mei Yilan, Yang Ruihan, Luo Qiudan, Zhang Jienian, Kou Xiaolin, Hu Jianfeng, Wang Yujie, Li Yue, Chen Rong, Zhang Zhengping, Yao Yuyuan, Sima Jian

发表时间：2024-4-

期刊：Cell and Bioscience

影响因子：6.1

DOI:10.1186/s13578-024-01230-8

Abstract

Background

Alzheimer’s disease (AD) is the most prevalent neurodegenerative disease with limited disease-modifying treatments. Drug repositioning strategy has now emerged as a promising approach for anti-AD drug discovery. Using 5×FAD mice and Aβ-treated neurons in culture, we tested the efficacy of Y-2, a compounded drug containing the antioxidant Edaravone (Eda), a pyrazolone and (+)-Borneol, an anti-inflammatory diterpenoid from cinnamon, approved for use in amyotrophic lateral sclerosis patients.

Results

We examined effects of Y-2 versus Eda alone by i.p. administered in 8-week-old 5×FAD mice (females) for 4 months by comparing cognitive function, Aβ pathologies, neuronal necroptosis and neuroinflammation. Using primary neurons and astrocytes, as well as neuronal and astrocytic cell lines, we elucidated the molecular mechanisms of Y-2 by examining neuronal injury, astrocyte-mediated inflammation and necroptosis. Here, we find that Y-2 improves cognitive function in AD mice. Histopathological data show that Y-2, better than Eda alone, markedly ameliorates Aβ pathologies including Aβ burden, astrogliosis/microgliosis, and Tau phosphorylation. In addition, Y-2 reduces Aβ-induced neuronal injury including neurite damage, mitochondrial impairment, reactive oxygen species production and NAD+ depletion. Notably, Y-2 inhibits astrocyte-mediated neuroinflammation and attenuates TNF-α-triggered neuronal necroptosis in cell cultures and AD mice. RNA-seq further demonstrates that Y-2, compared to Eda, indeed upregulates anti-inflammation pathways in astrocytes.